Autolus Therapeutics shares are trading higher after Truist Securities maintained a Buy rating on the stock and raised its price target from $6 to $9.
Portfolio Pulse from Benzinga Newsdesk
Autolus Therapeutics shares are trading higher after Truist Securities maintained a Buy rating on the stock and raised its price target from $6 to $9.
August 17, 2023 | 4:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Autolus Therapeutics' stock price is expected to increase in the short term as Truist Securities maintains a Buy rating and raises its price target from $6 to $9.
The news directly mentions Autolus Therapeutics and the action of Truist Securities, which maintained a Buy rating and raised its price target for the company. This is a positive signal for investors, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100